1119 related articles for article (PubMed ID: 9272128)
21. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance.
Uchiyama-Kokubu N; Watanabe T; Nakajima M
Anticancer Drugs; 2000 Aug; 11(7):583-90. PubMed ID: 11036963
[TBL] [Abstract][Full Text] [Related]
22. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.
Coley HM; Verrill MW; Gregson SE; Odell DE; Fisher C; Judson IR
Eur J Cancer; 2000 May; 36(7):881-8. PubMed ID: 10785593
[TBL] [Abstract][Full Text] [Related]
23. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators.
Krishna R; Mayer LD
Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):163-74. PubMed ID: 12678765
[TBL] [Abstract][Full Text] [Related]
24. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor.
Didier A; Loor F
Anticancer Drugs; 1996 Sep; 7(7):745-51. PubMed ID: 8949985
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
26. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
27. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.
Yamagishi T; Sahni S; Sharp DM; Arvind A; Jansson PJ; Richardson DR
J Biol Chem; 2013 Nov; 288(44):31761-71. PubMed ID: 24062304
[TBL] [Abstract][Full Text] [Related]
29. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Advani R; Saba HI; Tallman MS; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Sikic BI; Greenberg PL
Blood; 1999 Feb; 93(3):787-95. PubMed ID: 9920827
[TBL] [Abstract][Full Text] [Related]
30. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
[TBL] [Abstract][Full Text] [Related]
31. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O
Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923
[TBL] [Abstract][Full Text] [Related]
32. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Lehne G; De Angelis P; den Boer M; Rugstad HE
Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882
[TBL] [Abstract][Full Text] [Related]
33. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators.
Aszalos A; Ladányi A; Bocsi J; Szende B
Cancer Lett; 2001 Jun; 167(2):157-62. PubMed ID: 11369136
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppressors and reversion of multidrug-resistance.
Aouali N; Eddabra L; Macadré J; Morjani H
Crit Rev Oncol Hematol; 2005 Oct; 56(1):61-70. PubMed ID: 15978826
[TBL] [Abstract][Full Text] [Related]
36. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
[TBL] [Abstract][Full Text] [Related]
37. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.
Krishna R; Mayer LD
Eur J Pharm Sci; 2000 Oct; 11(4):265-83. PubMed ID: 11033070
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
39. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
40. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Lehne G; Mørkrid L; den Boer M; Rugstad HE
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):187-95. PubMed ID: 10783828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]